Working… Menu

Adjuvant PEG Intron in Ulcerated Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01502696
Recruitment Status : Unknown
Verified February 2019 by European Organisation for Research and Treatment of Cancer - EORTC.
Recruitment status was:  Active, not recruiting
First Posted : January 2, 2012
Last Update Posted : March 4, 2019
NCIC Clinical Trials Group
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC

Brief Summary:

Patients with an ulcerated melanoma with Breslow >1 mm, N0M0 have a significantly higher risk for relapse than patients with a non-ulcerated primary and about a 40-50% chance of developing stage IV disease to which they will almost invariably succumb. In stage I and II patients with an ulcerated primary who have been sentinel node (SN-staged) and found to be SN-negative there is still a 25-30% relapse risk.

The purpose of this study is to evaluate the effectiveness and safety when treated with PEG IFN alfa-2b for 2 years as compared to observation (no treatment), administered after adequate surgery has been performed for ulcerated primary cutaneous melanomas.

Condition or disease Intervention/treatment Phase
Ulcerated Melanomas Biological: PEG IFN alfa-2b Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Adjuvant Pegylated-Interferon-alpha2b (SylatronTM) for 2 Years Versus Observation in Patients With an Ulcerated Primary Cutaneous Melanoma With T(2-4)bN0M0: a Randomized Phase III Trial of the EORTC Melanoma Group.
Study Start Date : October 2012
Estimated Primary Completion Date : April 2019
Estimated Study Completion Date : April 2019

Arm Intervention/treatment
Experimental: PEG IFN alfa-2b Biological: PEG IFN alfa-2b
3µg/kg weekly injections

No Intervention: Observation

Primary Outcome Measures :
  1. Relapse-free survival (RFS) [ Time Frame: 6.3 years from first patient in ]

Secondary Outcome Measures :
  1. Occurence of Adverse Events [ Time Frame: 6.3 years from first patient in ]
    This study will use the International Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, for adverse event reporting.

  2. Overall survival (OS) [ Time Frame: 7.8 years from first patient in ]
  3. Distant metastases-free survival (DMFS) [ Time Frame: 7.8 years from first patient in ]
  4. Quality of life [ Time Frame: 6 years from from first patient in ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must be between 18-70 years old.
  • Subjects must have histologically documented ulcerated primary cutaneous melanomas with T(2-4)b N0M0.

Adequate resection of ulcerated primary cutaneous melanoma. 1 to 2 cm normal tissue excision margins according to Breslow thickness are recommended. In the head and neck areas and in case of locations distally on extremities, narrower margins are acceptable as long as they are radical (see Appendix F). Subjects must have recovered from the effects of recent surgery.

  • SNB must occur within 12 weeks prior randomization.
  • Subjects must have an ECOG performance status of 0 or 1 (See Appendix B).
  • Subjects must have adequate bone marrow, renal and hepatic function as defined by the following parameters obtained up to maximum 12 weeks prior to randomization:

    • Hematology:
    • WBC >= 3.0 x 109/L
    • Neutrophils > 1.5 x 109/L
    • Platelets > 100 x 109/L
    • Hemoglobin >= 9 g/dL or 5.6 mmol/L
    • Adequate Renal and Hepatic function:
    • Serum creatinine < 2.0 mg/dL or < 140 µmol/L
    • SGOT and SGPT < 2 times upper normal limit of laboratory normal (ULN)

Exclusion Criteria:

  • No mucosal melanoma nor ocular melanoma.
  • No evidence of nodal involvement confirmed by sentinel lymph node biopsy (SNB). Sentinel Node staging after the excision of the primary must be done between the date of final excision of the primary and the date of randomization.
  • No evidence of regional nor distant lymph node metastases nor satellites/in-transit metastases (even if they have been resected).
  • No evidence of distant metastasis on clinical examination, CT/MRI of full chest, abdomen and pelvis. Neck CT/MRI if head and neck primary.
  • No clinical evidence of brain metastasis.
  • No pregnant women
  • No breast feeding women
  • No patients with a medical condition requiring chronic systemic corticosteroids are not eligible.
  • No experimental therapy within 30 days prior to randomization in this study.
  • No prior chemotherapy, immunotherapy/vaccine, hormonal or radiation therapy for melanoma.
  • No prior treatment with interferon-alfa for any reason.
  • No history of prior malignancy within the past 5 years other than surgically cured non-melanoma skin cancer or cervical carcinoma in situ.
  • No severe cardiovascular disease, i.e. arrhythmias requiring chronic treatment, congestive heart failure (NYHA Class III or IV) nor symptomatic ischemic heart disease.
  • No thyroid dysfunction not responsive to therapy.
  • No poorly controlled (HBA1C>8%) diabetes mellitus or uncontrolled diabetes mellitus, i.e. elevated fasting serum glucose should be < 110% ULN).
  • No active autoimmune disease.
  • No active and/or uncontrolled infection, including active hepatitis.
  • No history of seropositivity for HIV.
  • No history of neuropsychiatric disorder requiring hospitalization.
  • Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01502696

Show Show 58 study locations
Sponsors and Collaborators
European Organisation for Research and Treatment of Cancer - EORTC
NCIC Clinical Trials Group
Layout table for investigator information
Study Chair: Alexander Eggermont, MD, PHD Institut Gustave Roussy, Paris, France
Layout table for additonal information
Responsible Party: European Organisation for Research and Treatment of Cancer - EORTC Identifier: NCT01502696    
Other Study ID Numbers: EORTC-18081
2009-010273-20 ( EudraCT Number )
First Posted: January 2, 2012    Key Record Dates
Last Update Posted: March 4, 2019
Last Verified: February 2019
Keywords provided by European Organisation for Research and Treatment of Cancer - EORTC:
ulcerated primary cutaneous melanoma
Stage II
PEG IFN alfa-2b
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Pathologic Processes
Interferon alpha-2
Peginterferon alfa-2b
Antiviral Agents
Anti-Infective Agents
Antineoplastic Agents